This site is intended for healthcare professionals

Libtayo receives positive CHMP opinion for the treatment in Europe of two advanced cancers, namely NSCLC and basal cell carcinoma. Regeneron + Sanofi

Read time: 1 mins
Last updated:28th Jun 2021
Published:27th May 2021
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) as monotherapy in two advanced cancers.
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest